Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush lifted their Q1 2025 earnings per share (EPS) estimates for Stoke Therapeutics in a note issued to investors on Tuesday, January 7th. Wedbush analyst L. Chico now expects that the company will earn ($0.56) per share for the quarter, up from their prior forecast of ($0.59). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.08) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($2.27) EPS.

Several other analysts also recently issued reports on the stock. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Leerink Partners began coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. Chardan Capital began coverage on shares of Stoke Therapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $24.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Stock Performance

NASDAQ STOK opened at $9.00 on Friday. The stock has a market capitalization of $476.70 million, a P/E ratio of -4.29 and a beta of 0.95. Stoke Therapeutics has a 1 year low of $4.09 and a 1 year high of $17.58. The business’s fifty day moving average is $11.91 and its two-hundred day moving average is $13.04.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently modified their holdings of the company. Lynx1 Capital Management LP grew its stake in shares of Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after purchasing an additional 1,488,371 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after purchasing an additional 1,123,500 shares during the last quarter. Logos Global Management LP bought a new stake in shares of Stoke Therapeutics during the second quarter valued at approximately $14,186,000. Marshall Wace LLP grew its stake in shares of Stoke Therapeutics by 550.1% during the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after purchasing an additional 982,451 shares during the last quarter. Finally, RTW Investments LP boosted its stake in Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after acquiring an additional 427,447 shares during the last quarter.

Insider Activity

In other news, General Counsel Jonathan Allan sold 13,666 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $13.61, for a total transaction of $185,994.26. Following the completion of the sale, the general counsel now owns 21,476 shares of the company’s stock, valued at approximately $292,288.36. This trade represents a 38.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Edward M. Md Kaye sold 6,170 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the sale, the chief executive officer now directly owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. The trade was a 8.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 62,849 shares of company stock valued at $809,421. Insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.